CN115501273A - Application of traditional Chinese medicine compound effective extract in preparation of medicine for resisting eimeria tenella - Google Patents
Application of traditional Chinese medicine compound effective extract in preparation of medicine for resisting eimeria tenella Download PDFInfo
- Publication number
- CN115501273A CN115501273A CN202110696685.8A CN202110696685A CN115501273A CN 115501273 A CN115501273 A CN 115501273A CN 202110696685 A CN202110696685 A CN 202110696685A CN 115501273 A CN115501273 A CN 115501273A
- Authority
- CN
- China
- Prior art keywords
- coccidiosis
- traditional chinese
- medicine
- eimeria tenella
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 59
- 241000223932 Eimeria tenella Species 0.000 title claims abstract description 17
- 150000001875 compounds Chemical class 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims description 9
- 239000000284 extract Substances 0.000 title description 4
- 208000003495 Coccidiosis Diseases 0.000 claims abstract description 36
- 206010023076 Isosporiasis Diseases 0.000 claims abstract description 36
- 229940079593 drug Drugs 0.000 claims abstract description 26
- 238000011282 treatment Methods 0.000 claims abstract description 13
- 240000004534 Scutellaria baicalensis Species 0.000 claims abstract description 8
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims abstract description 8
- 241000037740 Coptis chinensis Species 0.000 claims abstract description 7
- 239000000463 material Substances 0.000 claims abstract description 7
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 6
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 6
- ZSZFUDFOPOMEET-UHFFFAOYSA-N 2-(4-chlorophenyl)-2-[2,6-dichloro-4-(3,5-dioxo-1,2,4-triazin-2-yl)phenyl]acetonitrile Chemical compound C1=CC(Cl)=CC=C1C(C#N)C1=C(Cl)C=C(N2C(NC(=O)C=N2)=O)C=C1Cl ZSZFUDFOPOMEET-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229960000248 diclazuril Drugs 0.000 claims abstract description 5
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 5
- 235000011477 liquorice Nutrition 0.000 claims abstract description 5
- 239000003674 animal food additive Substances 0.000 claims description 8
- UKHWDRMMMYWSFL-UHFFFAOYSA-N Nicarbazin Chemical compound CC=1C=C(C)NC(=O)N=1.C1=CC([N+](=O)[O-])=CC=C1NC(=O)NC1=CC=C([N+]([O-])=O)C=C1 UKHWDRMMMYWSFL-UHFFFAOYSA-N 0.000 claims description 6
- 229940073485 nicarbazin Drugs 0.000 claims description 6
- OCINXEZVIIVXFU-UHFFFAOYSA-N 1-methyl-3-[3-methyl-4-[4-(trifluoromethylthio)phenoxy]phenyl]-1,3,5-triazinane-2,4,6-trione Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(SC(F)(F)F)C=C1 OCINXEZVIIVXFU-UHFFFAOYSA-N 0.000 claims description 2
- NHZLNPMOSADWGC-UHFFFAOYSA-N 4-amino-N-(2-quinoxalinyl)benzenesulfonamide Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CN=C(C=CC=C2)C2=N1 NHZLNPMOSADWGC-UHFFFAOYSA-N 0.000 claims description 2
- QKLPUVXBJHRFQZ-UHFFFAOYSA-N 4-amino-n-(6-chloropyrazin-2-yl)benzenesulfonamide Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CN=CC(Cl)=N1 QKLPUVXBJHRFQZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960002135 sulfadimidine Drugs 0.000 claims description 2
- ASWVTGNCAZCNNR-UHFFFAOYSA-N sulfamethazine Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ASWVTGNCAZCNNR-UHFFFAOYSA-N 0.000 claims description 2
- 229960003097 sulfaquinoxaline Drugs 0.000 claims description 2
- 229960000898 toltrazuril Drugs 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 241000287828 Gallus gallus Species 0.000 abstract description 35
- 230000000694 effects Effects 0.000 abstract description 22
- 241000238631 Hexapoda Species 0.000 abstract description 7
- 244000046146 Pueraria lobata Species 0.000 abstract description 5
- 235000010575 Pueraria lobata Nutrition 0.000 abstract description 5
- 239000008838 gegenqinlian Substances 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 5
- 235000013372 meat Nutrition 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 235000014347 soups Nutrition 0.000 abstract 1
- 235000013330 chicken meat Nutrition 0.000 description 31
- 230000001165 anti-coccidial effect Effects 0.000 description 13
- 210000003250 oocyst Anatomy 0.000 description 13
- 238000012360 testing method Methods 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 7
- 241000224483 Coccidia Species 0.000 description 6
- 235000014590 basal diet Nutrition 0.000 description 6
- 208000027503 bloody stool Diseases 0.000 description 6
- 208000035861 hematochezia Diseases 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- ZEFNOZRLAWVAQF-UHFFFAOYSA-N Dinitolmide Chemical compound CC1=C(C(N)=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O ZEFNOZRLAWVAQF-UHFFFAOYSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 206010059866 Drug resistance Diseases 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 229960003934 dinitolmide Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- 241001673966 Magnolia officinalis Species 0.000 description 3
- 210000004534 cecum Anatomy 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000223924 Eimeria Species 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 102000003896 Myeloperoxidases Human genes 0.000 description 2
- 108090000235 Myeloperoxidases Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 241000219780 Pueraria Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003640 drug residue Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 229940118019 malondialdehyde Drugs 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- KMUONIBRACKNSN-UHFFFAOYSA-N potassium dichromate Chemical compound [K+].[K+].[O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O KMUONIBRACKNSN-UHFFFAOYSA-N 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- 241000561734 Celosia cristata Species 0.000 description 1
- 241000218202 Coptis Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 description 1
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 210000001520 comb Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000028070 sporulation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Animal Husbandry (AREA)
- Birds (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a compound traditional Chinese medicine (modified Gegenqinlian decoction for short), which comprises the following medicinal materials in parts by weight: 30-35% of mangnolia officinalis, 15-20% of coptis chinensis, 10-15% of liquorice, 15-20% of kudzu root and 15-20% of scutellaria baicalensis. The inventor utilizes Eimeria tenella pathogeny to prepare a chicken coccidiosis model, and researches on modified Gegen Qinlian soup, and the results show that the five traditional Chinese medicines are combined to have good prevention and treatment effects on chicken coccidiosis, have obvious effect of inhibiting Eimeria tenella, have the insect-resistant index as high as 233.47, and have the insect-resistant effect superior to that of the conventional insect-resistant medicine diclazuril on the market. The invention is a medicine for preventing and treating chicken coccidiosis, which has good curative effect, no public nuisance and no residue, improves the immunity, the meat quality and the weight, is convenient to use, and provides a new choice for replacing chemical medicines for preventing and treating coccidiosis.
Description
Technical Field
The invention belongs to the technical field of treatment of avian eimeria infection, and particularly relates to application of a traditional Chinese medicine compound effective extract in preparation of a medicine for resisting eimeria tenella.
Background
Coccidiosis is an important common disease in the chicken industry, because coccidian oocyst survivability is strong and transmission path is wide, since eimeria found in 1870, the harm of coccidian is gradually emphasized by various figures in the world. At present, an intensive chicken farm becomes the most suitable place for coccidiosis outbreak, the morbidity reaches 50% -70%, the mortality reaches 20% -30%, and in severe cases reaches 80%, among various chicken diseases, the morbidity of coccidiosis is the highest, the development of poultry industry is seriously influenced, the egg yield is reduced, and the economic loss is often larger than that caused by chicken death. At present, the control of coccidiosis mainly depends on chemical drugs, but the drug resistance and drug residue caused by long-term abuse of chemical drugs become more serious, and the drug resistance problem of coccidia and the high morbidity and mortality caused by the drug resistance problem always prevent the healthy development of the chicken industry. In recent years, research on the application of Chinese herbal medicines in preventing and treating chicken coccidiosis has been advanced to a certain extent, and the Chinese herbal medicines can prevent and treat the coccidiosis and solve the medicine residue in meat and eggs.
The Chinese medicinal composition, GEGENQINLIAN decoction (GQD), comprises radix Puerariae, scutellariae radix, coptidis rhizoma, and Glycyrrhrizae radix. Oral administration of radix Puerariae can inhibit NF-kB activation by reducing Toll-like receptor 4 (TLR 4) expression in mucosa, down-regulate tumor necrosis factor (TNF-alpha), interleukin (IL) -6, IL-1 beta, IL-4 and other cytokines, reduce Myeloperoxidase (MPO) activity and Malondialdehyde (MDA) level, improve glutathione synthesis, relieve colonic oxidative stress, and relieve intestinal inflammation. The Gegenqinlian decoction can reduce the generation and expression of proinflammatory cytokines and inflammatory mediators and inhibit an NF-kB signal transduction pathway through the potential antioxidant effect of the Gegenqinlian decoction. GQD can also be combined with other drugs, and the combination therapy of GQD and anti-mouse PD-1 can down-regulate PD-1 and increase the expression of IL-2 and IFN-gamma, which indicates that the combination therapy can effectively restore T cell function by inhibiting check points. The cortex Magnolia officinalis has antibacterial, antiinflammatory, and antioxidant effects, and can be used for treating asthma, gastrointestinal diseases, and neurogenic diseases.
Disclosure of Invention
The invention aims to solve the technical problem of providing the application of the traditional Chinese medicine compound effective extract in preparing the anti-Eimeria tenella medicine, providing a new way for treating chicken coccidiosis and avoiding drug resistance and drug residue caused by chemical drug treatment.
In order to solve the technical problems, the invention adopts the following technical scheme:
a compound traditional Chinese medicine comprises the following medicinal materials in parts by weight: 30-35% of mangnolia officinalis, 15-20% of coptis chinensis, 10-15% of liquorice, 15-20% of radix puerariae and 15-20% of scutellaria baicalensis.
The compound traditional Chinese medicine is used as a feed additive, and the dosage of the feed additive is 500 g/ton of feed.
The traditional Chinese medicine compound is applied to the preparation of medicines for resisting eimeria tenella or treating coccidiosis.
The medicine for resisting Eimeria tenella or treating coccidiosis comprises the compound traditional Chinese medicine and a chemosynthetic anti-chicken coccidiosis medicine.
The chemosynthetic anti-coccidiosis drug is one or more of sulfamethazine, sulfaquinoxaline, sulfachloropyrazine, amproline, dinitrotolamine, nicarbazin, diclazuril and toltrazuril.
The medicine for resisting the eimeria tenella or treating the coccidiosis is used as a feed additive, and the dosage of the feed additive is 500 g/ton of feed.
Chicken coccidiosis is a common intestinal disease of the current free-range chickens, and the disease mainly causes bloody stool, diarrhea and the increase of feed-meat ratio due to the reduction of growth performance. According to the theory of Chinese veterinarian, the coccidiosis of chicks is a disease caused by the exopathic coccidiosis, which is caused by blood consumption and fluid damage of coccidiosis and dampness-heat retention in the spleen. So the sick chicken have poor appetite in the early stage. Lassitude, thin feces, mucus and blood in the feces, thirst and desire for drink, aversion to cold, white cockscomb, emaciation, exhaustion and death. The clinical symptoms caused by chicken coccidiosis are mainly bloody dysentery, and the treatment mainly comprises killing parasites, clearing heat and drying dampness. Accordingly, the inventor develops a compound traditional Chinese medicine (modified pueraria qinlian decoction for short) by modifying based on the pueraria qinlian decoction, and the compound traditional Chinese medicine comprises the following medicinal materials in parts by weight: 30-35% of mangnolia officinalis, 15-20% of coptis chinensis, 10-15% of liquorice, 15-20% of radix puerariae and 15-20% of scutellaria baicalensis. The method comprises the following steps: the magnolia officinalis and the kudzuvine root are heat-clearing and detoxifying drugs, have the effects of clearing heat, detoxifying, checking diarrhea and killing insects, and are monarch drugs; the coptis chinensis and the scutellaria baicalensis clear heat and dry dampness and thicken intestines to stop diuresis, so the coptis chinensis and the scutellaria baicalensis are ministerial drugs; licorice root, radix Glycyrrhizae is used as a guiding drug to coordinate the effects of the drugs and improve the therapeutic effects. The inventor utilizes Eimeria tenella pathogen to make a chicken coccidiosis model, and researches on modified Gegen Qinlian decoction, and the results show that the five traditional Chinese medicines are jointly applied, so that the chicken coccidiosis model has good prevention and treatment effects, has an obvious Eimeria tenella inhibition effect, has an insect resistance index as high as 233.47, and has an insect resistance effect superior to that of a conventional insect-resistant medicine diclazuril on the market.
Compared with the prior art, the invention has the following beneficial effects:
(1) The invention combines the good anticoccidial activity of the mangnolia officinalis and the intestinal protection effect of the Gegenqinlian decoction, and remarkably improves the problems of growth performance reduction, animal death and the like caused by coccidiosis.
(2) The traditional Chinese medicine composition disclosed by the invention is a medicine for preventing and treating chicken coccidiosis, which is good in curative effect, pollution-free, residue-free, convenient to use and capable of improving immunity, meat quality and weight, and does not cause any toxic and side effects on chicken, and a new choice is provided for replacing chemical medicines for preventing and treating coccidiosis.
Detailed Description
Preclinical testing
1. Material preparation
1.1 preparation of the drug
Adding raw materials of the modified kudzuvine root, scutellaria and coptis decoction: 937.5g of magnolia officinalis, 562.5g of coptis chinensis, 375g of liquorice, 562.5g of kudzuvine root and 562.5g of scutellaria baicalensis are mixed according to a proportion, the raw material of the modified kudzuvine root and scutellaria baicalensis decoction purchased and processed in a pharmacy is crushed and sieved by a 60-mesh sieve to be used as a basic raw material, and then the basic raw material and the powdery antibacterial drug are put into a mixer according to the weight part ratio and are mixed uniformly and mixed with feed according to a conventional method. The drugs, amounts, and modes of administration used in the examples are shown in table 1.
TABLE 1 pharmaceuticals and products of examples 1-4
The nicarbazin used in the examples is a conventional anticoccidial drug nicarbazin premix (25%, from Zhejiang Hui Neigang GmbH).
1.2 chicks: laying hens of 1 day old, provided by Beijing college of agriculture, are raised in a special animal house which is disinfected and free of coccidia; the chicken coop, the trough and the water tank are all disinfected strictly, and the chicken coop can be eaten freely and can drink purified water.
1.3 feed: example 1 was provided by northern Dacron farm feed mills as a blank control without any anticoccidial drug.
2. Experimental methods
2.1 test grouping
2000 chickens in the same batch are selected in the experiment, the treatment is completely and randomly divided into 4 treatments, each treatment is repeated for 5 times, each repetition is 100 times, and the same feeding mode is adopted. The group of example 1 (basal diet), the group of example 2 (3 kg of modified Gegen Qinlian decoction added to 1 ton of basal diet), the group of example 3 (3 kg of modified Gegen Qinlian decoction added to 1 ton of basal diet and 125 g of nicarbazin added to 1 ton of basal diet) and the group of example 4 (125 g of nicarbazin added to basal diet) were prepared.
2.2 Breeding management
The henhouse is cleaned and disinfected in a clean land before the test. And (3) test period: from 1 to 28 days old.
Feed intake and body weight were calculated every 7 days, diarrhea and bloody stool were recorded every 7-14 days, and every 7 days after 14 days.
Immunization procedure: performed according to the existing immunization program of the chicken farm.
3. Preventive contrast test
Randomly picked local chickens of 1 day old as the preventive contrast test subjects were randomly divided into 4 groups, after feeding for 7 days, the mental status, feed intake, feces condition and the like of the chicken flocks were observed and recorded every day, and finally the weight gain and feed conversion ratio of each group of chicks were calculated, and the results are shown in table 2.
Table 2 feed conversion rates FCR for examples 1-4
As shown in Table 2, the feed-meat ratio of example 2 is 0.09 lower than that of example 1 (basal diet group), which indicates that the modified Gegen Qinlian decoction technical can promote the growth of chicks and does not cause any toxic or side effect on the growth of chicks.
4. Therapeutic contrast test
4.1 test materials
4.1.1 preparation of the drug
The preparation of each group of test drugs is referred to 1.1, and the amounts and administration methods are shown in Table 3.
In the examples, the dinitolmide used was a conventional anti-coccidial dinitolmide premix (25% of Huixin animal pharmaceuticals Co., ltd., guangzhou) and the diclazuril used was a conventional anti-coccidial dinlazuril premix (0.5% of Shandong Xunda kang veterinary drugs Co., ltd.).
4.1.2 Chicken coccidia oocysts: eimeria tenella (Eimeria tenella) sporulated oocysts (given by the university of agriculture in China) are passaged and rejuvenated by two weeks of chickens before use, ceca are collected, oocysts are collected, the oocysts are counted at 28 ℃ until the sporulation rate reaches more than 80%, stored in a 2.5% potassium dichromate solution and stored in a refrigerator at 4 ℃ for use within one month.
4.1.3 chicks: 1 day old chicks are raised in a special animal house which is disinfected and fumigated in advance, the condition that the animal house, the coops, the water tanks and the material tanks are thoroughly disinfected and free from coccidium infection is ensured, and the chicks are fed with feed and water which are disinfected and sterilized at high temperature and are freely eaten; one week before animal coccidium model is made, the clinic symptoms of the chicken are carefully observed, whether the excrement contains coccidium oocysts is checked, weak chicken and chicken possibly infected with coccidium are eliminated, and the rest chicken are reserved.
4.1.4 feed: does not contain any anticoccidial drugs and various antibiotics.
4.2 test methods
Grouping: and (4) feather-by-feather weighing is carried out on the remaining 10-day-old chicks, the chicks with larger weight difference are eliminated and eliminated, the screened chicks with uniform weight are completely randomly divided into 10 groups, and the same feeding mode is adopted.
Making animal coccidia model: examples 7-15 chicks were orally drenched with Eimeria tenella sporulated oocysts 2.5 x 10 5 Individuals per feather, and the drugs after the corresponding mix are fed on the same day.
Obvious bloody stool appears on the 4 th day after the model building, the quantity of the bloody stool is recorded, all chicks are dissected 7.5 days after the model building, and the lesion degree of the caecum of the chicks is observed; finally, the relative weight gain and feed reward of each group of chicks and the coccidiosis resistance index (ACI) are calculated. The test groups are shown in Table 3.
TABLE 3 formulations and products of examples 6-15
The morbidity, cure rate and mortality of each group of local chickens are observed and recorded, and the efficacy judgment method and the standard anticoccidial index (ACI) are calculated according to the formula recommended by American merck company: ACI = (relative rate of weight gain + survival) one (oocyst value + lesion value); relative rate of gain = (test group gain ÷ blank control group gain) × 100%; survival = (number of surviving chicks per group ÷ total number of chicks per group) × 100%. Lesions were scored on a five-point scale as shown in table 4.
TABLE 4 lesion scores
The determination criteria of the drug effect are that when the ACI is more than or equal to 180, the effect is excellent, the ACI is more than or equal to 160 and less than or equal to 180, the effect is good, the ACI is more than or equal to 140 and less than or equal to 160, the effect is moderate, the ACI is more than or equal to 120 and less than or equal to 140, and the ACI is less than or equal to 120, the effect is invalid. Oocyst values are converted from the number of oocysts per gram of cecal content (OPG).
5. Results of the experiment
Example 6 No E.tenella sporulated oocysts were inoculated and the chicks were well-refreshed, fed normally and had no blood present.
Example 7 on day 2 after inoculation of Eimeria tenella sporulated oocysts, chicks developed symptoms of depression, stupefaction, anorexia, and the like; on day 4, significant bloody stools began and no death occurred, followed by gradual reduction of bloody stools.
Caesarean examination of chickens from example 8-15, ceca were taken and anticoccidial index was calculated for each group based on lesion score, relative weight gain, survival rate and oocyst value, and the results are shown in Table 5.
TABLE 5 evaluation of anticoccidial Effect
From the data in table 5, it can be seen that: the treatment effect of the medicine on the coccidiosis of the chicks is obviously better than that of a western medicine treatment group, and as can be seen from examples 6-11, the effect of the dinitolmide group alone is not obvious, and the coccidiosis resisting effect is obviously improved after the medicine is combined with the medicine; as compared with the groups of examples 6-7 and 12-15, in this experiment, the modified Gegen Qinlian decoction showed a certain anti-coccidiosis effect at a lower dosage equivalent to 125 mg/kg of feed in the monomer formula. The blood and excrement discharge of the chicken in the administration group is obviously reduced compared with that of the control group; lesion scores were also significantly reduced compared to the control group. In addition, the monomer formula can obviously increase the weight of chickens and improve the growth performance of the broiler chickens. In addition, the highest anticoccidial index of the dinitolmide and the anticoccidial index of the invention only reaches 233.47, and the dinitolmide and the anticoccidial index have high anticoccidial effect.
Claims (6)
1. The compound traditional Chinese medicine is characterized by comprising the following medicinal materials in parts by weight: 30-35% of mangnolia officinalis, 15-20% of coptis chinensis, 10-15% of liquorice, 15-20% of radix puerariae and 15-20% of scutellaria baicalensis.
2. The compound traditional Chinese medicine as a feed additive of claim 1, wherein the dosage of the feed additive is 500 g/ton of feed.
3. The use of the compound of claim 1 in the preparation of a medicament for the treatment of eimeria tenella or coccidiosis.
4. An anti-eimeria tenella or coccidiosis treatment drug, which is characterized by comprising the compound traditional Chinese medicine and the chemosynthesis anti-coccidiosis drug according to claim 1.
5. The anti-eimeria tenella or coccidiosis treatment drug of claim 4, wherein said chemosynthetic anti-coccidiosis drug is one or more of sulfamethazine, sulfaquinoxaline, sulfachloropyrazine, amproline, dinitrotolamine, nicarbazin, diclazuril, toltrazuril.
6. The drug against Eimeria tenella or coccidiosis in therapy as feed additive in claim 4, wherein the feed additive is used in an amount of 500 g/ton of feed.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110696685.8A CN115501273A (en) | 2021-06-23 | 2021-06-23 | Application of traditional Chinese medicine compound effective extract in preparation of medicine for resisting eimeria tenella |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110696685.8A CN115501273A (en) | 2021-06-23 | 2021-06-23 | Application of traditional Chinese medicine compound effective extract in preparation of medicine for resisting eimeria tenella |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115501273A true CN115501273A (en) | 2022-12-23 |
Family
ID=84499340
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110696685.8A Pending CN115501273A (en) | 2021-06-23 | 2021-06-23 | Application of traditional Chinese medicine compound effective extract in preparation of medicine for resisting eimeria tenella |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115501273A (en) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001022934A2 (en) * | 1999-09-24 | 2001-04-05 | Yng Wong Quing Non | Delivery of small doses of ingestible treatments |
CN101167918A (en) * | 2007-10-25 | 2008-04-30 | 杨成全 | Traditional Chinese medicinal preparation for increasing immunity of pig or poultry |
CN101543261A (en) * | 2009-04-20 | 2009-09-30 | 重庆开洲牧业科技开发有限公司 | Chinese medicinal herb additive for meat chickens and application |
JP2013032351A (en) * | 2011-07-04 | 2013-02-14 | Takeda Chem Ind Ltd | Herbal medicine or crude medicine formulation and method for producing the same |
CN103721147A (en) * | 2013-10-23 | 2014-04-16 | 青岛华仁技术孵化器有限公司 | Traditional Chinese medicine composition for treating chicken coccidiosis |
CN104337967A (en) * | 2014-10-21 | 2015-02-11 | 郑州后羿制药有限公司 | Traditional Chinese medicine composition for treating coccidiosis in chicken and preparation method of traditional Chinese medicine composition |
CN105056121A (en) * | 2015-08-07 | 2015-11-18 | 北京农业职业学院 | Radix rubiae-containing traditional Chinese medicine composition used for preventing eimeria tenella disease |
CN105343727A (en) * | 2015-11-28 | 2016-02-24 | 殷志杰 | Traditional Chinese medicine preparation for treating chicken coccidiosis |
CN108245654A (en) * | 2017-12-30 | 2018-07-06 | 凤阳高科动物保健品厂 | A kind of oral liquid for preventing chicken coccidiasis |
-
2021
- 2021-06-23 CN CN202110696685.8A patent/CN115501273A/en active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001022934A2 (en) * | 1999-09-24 | 2001-04-05 | Yng Wong Quing Non | Delivery of small doses of ingestible treatments |
CN101167918A (en) * | 2007-10-25 | 2008-04-30 | 杨成全 | Traditional Chinese medicinal preparation for increasing immunity of pig or poultry |
CN101543261A (en) * | 2009-04-20 | 2009-09-30 | 重庆开洲牧业科技开发有限公司 | Chinese medicinal herb additive for meat chickens and application |
JP2013032351A (en) * | 2011-07-04 | 2013-02-14 | Takeda Chem Ind Ltd | Herbal medicine or crude medicine formulation and method for producing the same |
CN103721147A (en) * | 2013-10-23 | 2014-04-16 | 青岛华仁技术孵化器有限公司 | Traditional Chinese medicine composition for treating chicken coccidiosis |
CN104337967A (en) * | 2014-10-21 | 2015-02-11 | 郑州后羿制药有限公司 | Traditional Chinese medicine composition for treating coccidiosis in chicken and preparation method of traditional Chinese medicine composition |
CN105056121A (en) * | 2015-08-07 | 2015-11-18 | 北京农业职业学院 | Radix rubiae-containing traditional Chinese medicine composition used for preventing eimeria tenella disease |
CN105343727A (en) * | 2015-11-28 | 2016-02-24 | 殷志杰 | Traditional Chinese medicine preparation for treating chicken coccidiosis |
CN108245654A (en) * | 2017-12-30 | 2018-07-06 | 凤阳高科动物保健品厂 | A kind of oral liquid for preventing chicken coccidiasis |
Non-Patent Citations (1)
Title |
---|
胡功政: "新全实用兽药手册", vol. 1, 30 September 2009, 河南科学技术出版社, pages: 126 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103704513B (en) | Feed for treating swine plague and preparation method thereof | |
KR20130013712A (en) | A process for producing animal pharmaceutical comprising natural herbs and having a preventing activity of animal's diarrhea | |
EP2236149A1 (en) | Medicinal composition | |
CN1295982C (en) | Fish growth promoting prepn. made up of Chinese herb medicines | |
CN102755399A (en) | Traditional Chinese medicine composition for resisting coccidiosis | |
CN102988363B (en) | Medicine for treating poultry proventriculitis and necrotic enteritis and preparation method thereof | |
CN105663546B (en) | Traditional Chinese medicine composition for treating proventriculitis of chicken | |
CN101209297A (en) | Compound Chinese medicinal granule for treating chicken coccidiosis | |
CN101209330A (en) | Compound Chinese medicinal granule with heat-clearing and detoxication, worm-expelling and liver-protecting efficacy | |
CN101209296A (en) | Chinese medicinal granule with worm-expelling liver-caring, hemostasis and dysentery-stopping efficacy | |
CN103285255B (en) | Anti-coccidiosis pharmaceutical composition as well as preparation method and use thereof | |
CN114557994B (en) | Application of usnic acid and salt preparation thereof in preparation of anti-chicken coccidiosis medicines or feed additives | |
CN102805772B (en) | Application of coptis chinensis, amur cork-tree bark, Chinese rhubarb and skullcap dysentery inhibiting particles to preparation of medicines for treating intestinal diseases of poultry, and medicinal composition formed by compounding particles | |
CN115501273A (en) | Application of traditional Chinese medicine compound effective extract in preparation of medicine for resisting eimeria tenella | |
CN111760004B (en) | Traditional Chinese medicine granules for preventing and treating livestock and poultry influenza and application thereof | |
CN111467407B (en) | Application of black tiger fruit extract | |
CN109966289B (en) | Application of daphnetin in resisting chicken coccidiosis | |
CN109432287B (en) | Traditional Chinese medicine oral liquid for preventing and treating excessive heat syndrome of poultry qi system and preparation method thereof | |
CN101953962B (en) | Chinese traditional medicine and granular preparation for treating cestodosis and preparation method thereof | |
CN105770054A (en) | Pharmaceutical composition for preventing and treating chicken coccocidiosis, additive and feed | |
CN107349376B (en) | Anti-coccidiosis probiotic medicine and preparation method and application thereof | |
CN110755604A (en) | Pharmaceutical composition for preventing and treating poultry adenofibromyositis and application thereof | |
CN114073728B (en) | Traditional Chinese medicine composition for preventing and treating salpingitis of laying hens and preparation method thereof | |
CN102240335B (en) | Compound salinomycin preparation | |
CN110141590B (en) | Kosteletzkya virginica traditional Chinese medicine composite composition for preventing and treating chicken coccidiosis and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |